Phase II trial of paclitaxel, ifosfamide, and cisplatin (TIP) for previously untreated patients (pts) with intermediate- or poor-risk germ cell tumors (GCT).
Darren Richard Feldman
No relevant relationships to disclose
James Hu
No relevant relationships to disclose
Tanya B. Dorff
No relevant relationships to disclose
Sujata Patil
No relevant relationships to disclose
Lindsay Joy Van Alstine
No relevant relationships to disclose
Lamia Momen
No relevant relationships to disclose
Maryann Carousso
No relevant relationships to disclose
Amanda Hughes
No relevant relationships to disclose
Jolie Snively-Solomon
No relevant relationships to disclose
Charlean Ketchens
No relevant relationships to disclose
Joel Sheinfeld
No relevant relationships to disclose
Manjit S. Bains
No relevant relationships to disclose
Dean F. Bajorin
Consultant or Advisory Role - Bristol-Myers Squibb
Research Funding - Amgen
George J. Bosl
No relevant relationships to disclose
Robert John Motzer
No relevant relationships to disclose
David I. Quinn
No relevant relationships to disclose